| Autor: |
Rehman A; Department of Medical Oncology, Jinnah Medical Postgraduate Center (JMPC), Karachi, Pakistan., Haider G; Department of Medical Oncology, Jinnah Medical Postgraduate Center (JMPC), Karachi, Pakistan., Ramchand A; Department of Medical Oncology, Jinnah Medical Postgraduate Center (JMPC), Karachi, Pakistan., Anaum -; Department of Medical Oncology, Jinnah Medical Postgraduate Center (JMPC), Karachi, Pakistan., Nawaz Khan S; Department of Medical Oncology, Jinnah Medical Postgraduate Center (JMPC), Karachi, Pakistan., Mahar F; Department of Medical Oncology, Jinnah Medical Postgraduate Center (JMPC), Karachi, Pakistan., Mahmood R; Atomic Energy Medical Center (AEMCK), Jinnah Medical Postgraduate Center (JMPC), Karachi, Pakistan., Saher S; Department of Medical Oncology, Jinnah Medical Postgraduate Center (JMPC), Karachi, Pakistan., Khattak YR; Hayatabad Medical Complex, Peshawar, Pakistan., Aqeel MA; Department of Medical Oncology, Jinnah Medical Postgraduate Center (JMPC), Karachi, Pakistan. |
| Abstrakt: |
Induction followed by concurrent chemoradiation (CCRT) is the standard of care for locally advanced nasopharyngeal carcinoma (LANPC). This study evaluated and compared the efficacy of two regimens of neoadjuvant chemotherapy along with CCRT in LANPC. Patients with LANPC were randomly divided in Group I (receiving neoadjuvant gemcitabine and cisplatin) and Group II (receiving neoadjuvant docetaxil, cisplatin and fluorouracil). Both groups also received concurrent single agent (i.e., cisplatin) chemotherapy and radiotherapy (70Gy). Treatment response was assessed at 8 weeks after the completion of CCRT using RECIST criteria. A total of 68 LANPC patients were enrolled. Group I comprised of 32 patients, with male to female ratio of 2.2, a mean (range, median) age of 38.6±11.3 (19-58, 36) years. Group II comprised of 36 patients, with male to female ratio of 3.5, mean (range, median) age of 40.9 ±11.6 (17-63, 40) years. The complete response was higher whereas the partial response was lower in Group I as compared to Group II (23/32 versus 16/36 and 06/32 versus 18/36, respectively). LANPC patients receiving gemcitabine plus cisplatin based neoadjuvant chemotherapy showed higher response, as compared with docetaxil, cisplatin and fluorouracil based neoadjuvant chemotherapy. |
